Saredutant

Saredutant is a drug that was under development by Sanofi-Aventis for the treatment of anxiety and depression. It acts as a selective neurokinin 2 receptor antagonist.

History

Saredutant was first developed by the French multinational pharmaceutical company Sanofi-Aventis. The drug was in the late stages of clinical trials for the treatment of anxiety and depression, but development was discontinued in 2009.

Mechanism of Action

Saredutant works by selectively blocking neurokinin 2 receptors. These receptors are found in the brain and are involved in the regulation of mood and anxiety. By blocking these receptors, Saredutant can potentially reduce symptoms of anxiety and depression.

Clinical Trials

Several clinical trials were conducted to assess the efficacy and safety of Saredutant. These trials showed promising results, with Saredutant demonstrating a significant reduction in symptoms of anxiety and depression compared to placebo. However, the development of the drug was discontinued before it could be approved for use.

Discontinuation

The development of Saredutant was discontinued in 2009. The reasons for this are not publicly disclosed, but it is speculated that the decision was based on a combination of factors including the results of the clinical trials, the potential market for the drug, and the company's overall strategic direction.

See Also

• Neurokinin 2 receptor
• Sanofi-Aventis
• Clinical trial

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

• 
  Saredutant